November 3, 2026 | Reporting period: October 26–November 1
Federal medical cannabis registration became an operating reality last week. The Justice Department announced approvals for more than 900 dispensaries, while DEA issued guidance requiring qualifying applicants to establish compliant supply chains by November 29. A Minnesota application also exposed a consequential disagreement over dual medical and adult-use licenses.
Elsewhere, Jushi reported stronger wholesale sales and continued Virginia expansion preparations. SNDL disclosed manufacturing losses, workforce reductions and a larger economic interest in Parallel. New York changed its cannabis labor requirements, and an Australian advertising judgment clarified the financial exposure attached to medical cannabis promotion.
1. DEA approves more than 900 dispensaries and sets a November 29 supply-chain deadline
On October 30, the Justice Department announced federal registrations for more than 900 medical marijuana dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia. These approvals implement the medical cannabis rescheduling order issued in April. The separate proceeding concerning broader marijuana rescheduling remains distinct.
DOJ says manufacturers and distributors face additional review, including facility inspections, production controls and quota determinations. A state license alone does not confer federal registration. DOJ announcement. United States Department of Justice
The immediate supply-chain development is DEA’s October 30 guidance. Businesses that submitted complete applications and fees between April 28 and June 26 can qualify as “Timely Applicants,” allowing specified activities while their applications remain pending. They can transact with other qualifying timely applicants and DEA registrants.
DEA expects timely applicants to verify counterparties and establish compliant supply chains by November 29. Its stated due-diligence steps include checking application confirmation numbers or registration certificates, verifying active state licenses and retaining records.
There are important qualifications. Timely dispensary and distributor applicants can continue handling otherwise authorized inventory acquired before the guidance, including inventory from suppliers outside those categories. A narrow testing exception permits small quantities to go to certain in-state, nonregistered laboratories when qualifying DEA-registered testing is unavailable under the conditions described in the guidance. This is agency guidance explaining existing requirements, rather than a newly enacted statute. DEA’s four-page guidance. deadiversion.usdoj.gov
Minnesota illustrates an unresolved barrier. Marijuana Moment reported October 30 that DEA issued an order to show cause to Minneapolis operator In-Dispensary, objecting to Minnesota’s dual-purpose licensing, certain veteran certification provisions and permitted hemp-derived products. The business can seek a hearing or submit a corrective-action plan. That procedural posture matters: this is a contested registration issue, not a shutdown of Minnesota’s state-authorized market. Reporting and linked order. Marijuana Moment
2. Jushi’s wholesale revenue rises 40%, while Virginia investment remains financing-dependent
Jushi’s October 28 results showed third-quarter revenue of US$70.5 million, up 7% year over year. Wholesale revenue increased 40% to $9.7 million, while retail revenue rose 3.5% to $60.8 million. Retail units sold increased 8.4%, faster than retail revenue, alongside continuing pricing pressure.
Management attributed wholesale growth to improved product quality, greater production volumes and broader distribution. Those are management’s explanations; the release does not provide cultivation yield or cost-per-gram figures that independently quantify the contribution of each factor.
Virginia delivered a second consecutive quarter of record retail revenue, with year-over-year growth at all six dispensaries. Jushi said it is advancing cultivation and processing projects and exploring financing alternatives ahead of the scheduled July 2027 adult-use launch.
The financing context is material. Quarterly operating cash flow was $3.5 million, compared with $6.1 million a year earlier; capital expenditure was $2.9 million. Jushi reported a $12.5 million net loss and $215.6 million of gross debt subject to scheduled repayments, excluding specified obligations. Its Virginia preparations are underway, but the disclosure does not establish that expansion financing or additional producing capacity is complete.
Source: Jushi’s unaudited third-quarter results. globenewswire.com
3. SNDL cuts manufacturing staff as cannabis production records a negative gross margin
SNDL’s October 27 results exposed a sharp divergence between its Canadian cannabis retail and production businesses.
Cannabis Operations revenue fell 27.7% year over year to CA$27.0 million, with a negative 6% gross margin. The segment recorded a $64.7 million operating loss, including a $52 million noncash goodwill impairment. SNDL also identified $6 million of other impacts, principally inventory adjustments associated with exiting domestic dried flower and Jeeter cost variances.
During the quarter, SNDL reduced the workforce at its Kelowna manufacturing facility by more than 30%. Management expects cost reductions to begin benefiting fourth-quarter results and has initiated a strategic review that could include asset divestitures and productivity initiatives. Savings remain an expectation until subsequent results demonstrate them.
The same disclosure reported that participation in Parallel’s rights offering increased SNDL’s indirect equity interest from approximately 67% to 92%. SNDL is evaluating a structure to own and consolidate Parallel’s U.S. medical operations directly while maintaining Nasdaq compliance; that structure is not yet finalized.
Source: SNDL’s third-quarter financial and operating disclosure. globenewswire.com
4. New York repeals mandatory labor peace agreements; wage-board removal still requires legislation
Governor Kathy Hochul signed S10643 on October 28 as Chapter 369. The law repeals cannabis licensing provisions requiring labor peace agreements.
The wage-board issue requires a more precise description than headlines suggesting the proposal was simply vetoed. The signed legislation contains wage-board and additional disclosure provisions scheduled to take effect January 31, 2027. Hochul secured an agreement with legislative leaders to remove those provisions through subsequent legislation.
That agreement is consequential, but it is not the same as an enacted amendment. Reporting on the governor’s approval memo also says the planned changes would allow licensing priority for applicants voluntarily entering labor peace agreements.
For employers and workers, the immediate licensing change and the prospective wage-board change therefore sit on different timelines. The next legislative text will determine how the negotiated agreement becomes law.
Sources: New York Senate bill, text and action history; reporting on Hochul’s approval memo. nysenate.gov
5. Cannabis testing research reports a four-minute identification method, with a 1% decision threshold
Research indexed October 27 in Analytical Methods describes a faster forensic approach to identifying marijuana using copper-phosphine chemistry and paper-spray mass spectrometry.
The authors report that the method distinguished THC without interference from CBD and correctly classified 34 of 36 cannabis samples. Elevated cannabinol concentrations accounted for the two misidentifications.
The important limitation is the 1% THC decision threshold used in the study. That differs from the 0.3% threshold underlying the hemp distinction discussed by the authors. The samples were also decarboxylated and extracted before analysis.
The reported four-minute identification time is promising for forensic throughput. It does not establish a replacement for a regulated product-release panel, a validated test at the 0.3% boundary, or a four-minute sample-to-certificate workflow. The useful finding is narrower: a potential route around time-consuming chromatographic separation, with CBN interference still requiring attention.
Sources: Original paper DOI; authors’ abstract reproduced by JoVE. JoVE Visualize
6. Australian court imposes A$6.95 million in medical cannabis advertising penalties
Australia’s Therapeutic Goods Administration announced October 30 that the Federal Court ordered CDA Clinics QLD to pay A$6.5 million, with another A$450,000 imposed on former director Dr. Benjamin Jansen for aiding and abetting the conduct.
The court found unlawful promotion of medicinal cannabis, including prescription-only and unapproved medicines, and prohibited or restricted representations concerning serious conditions.
The judgment’s relevance extends beyond individual advertising claims. As described by TGA, the court considered the website, blog posts and Facebook posts together as a deliberate commercial strategy encouraging engagement with the clinic and access to CBD products.
For businesses serving Australia, the finding directly concerns how patient acquisition is conducted. Publishing material as a blog or educational content does not, by itself, determine whether it is advertising. This was an announced court penalty, following proceedings initiated in 2023, rather than a new advertising prohibition.
Source: TGA announcement and linked judgment. Therapeutic Goods Administration (TGA)
New licenses and market openings
Minnesota’s October 26 application table reports 408 issued cannabis business licenses, including 299 microbusinesses, 24 cultivators and 20 retailer licenses. These categories do not translate directly into open-store counts: microbusinesses can include retail activities, and issued licenses do not establish operating status. OCM license data. mn.gov
For Kentucky, Texas and Virginia, this review did not establish a new state application window or opening announcement during the reporting period. Texas and Virginia are included in the federal dispensary registration rollout above; federal registration should not be counted as a newly opened state dispensary.
What to watch next
November 16, 4 p.m. Central: Minnesota closes its current cannabis event-organizer application ahead of January 2027 changes. OCM recommends at least 45 days for application review. OCM application guidance. mn.gov
November 29: DEA’s deadline for timely applicants to complete counterparty verification and establish compliant supply chains. Watch manufacturer and distributor approvals alongside dispensary registrations.
New York’s next legislative session: The actual amendment removing wage-board and disclosure provisions, including the final treatment of voluntary labor peace agreements.
Next operating disclosures: Whether SNDL’s manufacturing reductions improve margins, and whether Jushi identifies financing and commissioning milestones for Virginia.
